Using one-to-many urine proteome comparisons to provide clues for fever of unknown origin

Chenyang Zhao^{1#}, Lilong Wei^{2#}, Jing Wei¹ & Youhe Gao^{1*}

¹ Gene Engineering Drug and Biotechnology Beijing Key Laboratory, College of Life Sciences, Beijing Normal University, Beijing 100875, China

² China-Japan Friendship Hospital, Beijing 100029, China

*Corresponding author.

#These authors contributed equally to this work.

Abstract

Objective: To provide diagnostic evidence and clues for patients with fever of unknown origin (FUO) through urine proteomics analysis.

Methods: Urine samples of FUO were one-to-many analysed by using liquid chromatography tandem mass spectrometry(LC-MS/MS) to identify differential proteins and related biological pathways. One-to-many analysis means a comparative analysis of one sample to many controls.

Results: We observed biological pathways related to fever, such as LXR/RXR activation, FXR/RXR activation and acute phase response signaling, etc., which indicates that urine can obviously distinguish disease from health status. In addition, we found that the results of each sample were different, which highlight the necessity of one-to-many analysis.

Conclusions: The combined method of urine proteomics and one-to-many analysis can provide clues for FUO, and might also be applied to the exploration of any unknown disease.

Keywords: proteomics; urine; fever of unknown origin

1. Introduction

Fever is a common phenomenon in clinical manifestations. Since the concept of fever of unknown origin (FUO) was first proposed in 1961^[1], it has been an urgent problem to be solved in the field of medical diagnosis over the past 60 years. FUO refers to a type of disease that has a fever for more than 3 consecutive weeks with a body temperature of more than 38.3°C several times and cannot be confirmed after multiple examinations for at least a week. According to relevant literature reports, there are more than 200 aetiologies that can cause fever, such as bacterial or viral infections, neoplastic diseases and so on^[2]. Despite the great development of medical diagnostic technology, there are still some doubts about the exact diagnosis of FUO patients. It is difficult to apply medicine to patients without clear aetiology. Using drugs blindly can delay the condition, and it is also a waste of medical resources. Combining the above problems, it is a challenge for us to provide new diagnostic methods for FUO patients, provide clues for diagnosis, and help the generation and verification of diagnosis.

Urine is a way for the body to excrete metabolic wastes. Without the control of homeostatic mechanisms, urine can accumulate small changes from the whole body, which is earlier and more sensitive than blood^[3]. A large number of studies have shown that urine is a good source of disease biomarkers. For example, in a tumor-bearing rat model constructed by subcutaneous injection of Walker-256 cells, it was found that urine protein changes with the growth of tumor by monitoring the progression of cancer and urine protein^[4]. At the same time, in the Walker-256 tail-vein injection rat model, it was found that when tumors grew in different organs, the urine proteome was different, which indicates the differential diagnostic ability of urine. For another example, in a rat model of drug-induced chronic pancreatitis, it was found that significant changes in urinary proteins reported to be associated with pancreatitis had occurred before pathological visualization^[6], which reflected the early and highly sensitive nature of urine. All of these examples provided the basis for the early diagnosis of urine.

In this study, we pioneered a new method of comparison named one-to-many analysis, which means a comparative analysis of a patient and a group of healthy people. We believe that it is difficult to group patients into one group for analysis and comparison in the study of unknown disease. We have no definite evidence to group patients according to their characteristics, because of the unknowability of the disease. In actual clinical applications, doctors often judge a person for a disease based on his or her different performance which differs from the general public. In other words, we compare a person with all normal people, and beyond the normal range, there is a possibility of disease. Although there are differences among normal people, these differences fluctuate within a normal range. Through homogenization treatment within the group, a parameter closer to that of normal people can be obtained. When multiple proteins of patients with unknown diseases are found to differ from this parameter, we can analyse differential proteins by using existing bioinformatics methods to find abnormal biological processes or even damaged organs, to infer unknown diseases. Therefore, we carried out unlabelled quantitative proteomics analysis on the urine of each FUO sample to find biological pathways related to disease through differential proteins, and to provide clues and basis for the clinical diagnosis of FUO.

2. Methodology (Design/Approach)

2.1 Urine collection and ethics statement

This experiment was based on the reuse of discarded samples from Laboratory Medicine, and the process did not involve any patient identity information. We did not influence any treatment of the patient, nor did we recommend any clinical or auxiliary examination to the patient. The knowledge generated in this study is in the research stage, only for the acquisition of FUO clues.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

A total of 13 urine samples were collected from 13 patients with fever on admission at China–Japan Friendship Hospital in Beijing, and the patients' age ranged from 32 to 88 years. Eight healthy urine samples were collected from healthy donors of health care workers at Beijing Youan Hospital. Approximately 10–15 ml of midstream specimens of the morning urine was collected and stored at -80°C .

Two urine samples were abnormal in the test and clinically verified with urinary protein phenomena, which did not meet the sampling standards of this experiment, and as a result, they were excluded. All patients had fever at admission. On the day of urine sample collection, the patient's temperature is recorded in Table 1. All participants signed informed consent forms, and the study received ethical approval from China–Japan Friendship Hospital (No. 2019–42–K30).

2.2 Urine sample preparation

Four millilitres of urine sample reheated at 37°C was centrifuged at 4°C and 12,000g for 20min to remove cell and cell debris and retain the supernatants. Next, 20 mM dithiothreitol (DTT) was added and heated at 99.2°C for 10 min to cool to room temperature. Then 50 mM iodoacetamide (IAA) was added and mixed at room temperature for 40 min in the dark. After the reaction finished, the supernatants were placed into new Eppendorf tubes and mixed with four volumes of ethanol at -20°C overnight to precipitate protein. Mixed liquid was centrifuged at 4°C and 10,000g for 30min, and the precipitate was retained and dried. Proper lysis buffer (8 mol/L urea, 2 mol/L thiourea, 50 mmol/L Tris, and 25 mmol/L DTT) was added to redissolve the protein precipitate and was mixed at 4°C for 2h. The supernatants were retained after centrifugation at 4°C and 12,000g for 30min, and each sample's protein concentration was measured by the Bradford method.

The FASP method^[7] was used to digest urine protein with trypsin (Trypsin Gold, Mass Spec Grade, Promega, Fitchburg, Wisconsin, USA). One hundred micrograms of urine protein was added in the membrane of a 10KD ultrafiltration tube (Pall, Port Washington, NY) and washed twice with UA (8 M urea, 0.1 mol/L Tris–HCl, pH 8.5) and NH_4HCO_3 (25 mmol/L) at 14,000 g for 40 min at 18°C . Then, the urine protein was resuspended in 25mmol/L NH_4HCO_3 and digested by trypsin (enzyme to protein ratio of 1:50) at 37°C for 14 h–16 h. We obtained the peptides after two centrifugations at 4°C and 12,000g for 30min. These peptides were desalted using Oasis HLB cartridges (Waters, Milford, MA) and then dried by Speed Vac (Thermo Fisher Scientific, Bremen, Germany). Then, the peptides were stored at -80°C .

2.3 Peptide fractionation

We applied a method to improve the ability to identify low–abundance peptides. The digested peptides were redissolved in 0.1% formic acid and quantified to $0.5\text{ }\mu\text{g}/\mu\text{L}$ which was measured by the BCA method (Thermo Scientific). A pooled sample (73.5 μg , 3.5 μg of each sample) from 21 samples was loaded onto an equilibrated, high–pH, reversed–phase fractionation spin column (84868, Thermo Scientific) to generate the spectral library for subsequent analysis. Two fractions were collected by pooled sample and water. The remaining eight different fractions were collected by a step gradient of increasing acetonitrile concentrations (5.0, 7.5, 10.0, 12.5, 15.0, 17.5, 20.0 and 50.0% acetonitrile) in a volatile high–pH elution solution. Then the ten fractions were dried by Speed Vac (Thermo Scientific, Bremen, Germany) and resuspended in 20 μL of 0.1% formic acid for LC–MS/MS analysis.

2.4 LC–MS/MS analysis

The iRT reagent (Biognosys, Switzerland) was used to calibrate the retention time of the extracted peptide peaks and it was added at a ratio of 1:10 v/v to all of the peptide samples. For analysis, 1 μg of each peptide sample was loaded onto a trap column

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

(75 $\mu\text{m} \times 2\text{ cm}$, 3 μm , C18, 100 Å) and separated on a reverse-phase C18 column (50 $\mu\text{m} \times 15\text{ cm}$, 2 μm , C18, 100 Å) using the EASY-nLC 1200 HPLC system (Thermo Fisher Scientific, Waltham, MA). The elution gradient was 4%–35% buffer B (0.1% formic acid in 80% acetonitrile, flow rate, 0.4 $\mu\text{L}/\text{min}$) for 90 min. Eluted peptides were analysed by using an Orbitrap Fusion Lumos Tribrid Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).

To generate the spectral library, the ten fractions from the reversed-phase fractionation spin column were analysed by data-dependent (DDA) MS/MS acquisition mode with a resolution of 120,000 in full scan mode and 30,000 in MS/MS mode. The full scan was performed in the Orbitrap from 350–1,500 m/z , and the high-energy collisional dissociation (HCD) energy was set to 30%. The mass spectrometric parameters included the following: the automatic gain control (AGC) target was set to $4e5$; the maximum injection time was 45 ms.

Twenty-one single peptide samples were analysed by data-independent (DIA) MS/MS acquisition mode, and the variable isolation window of the DIA method with 36 windows was applied to DIA acquisition. The mass parameters contained the following: the full scan was obtained from 350 to 1,500 m/z with a resolution of 60,000, and the DIA scan was obtained from 200 to 2,000 m/z with a resolution of 30,000; the HCD energy was set to 32%; the AGC target was set to $1e6$ and the maximum injection time was 100 ms.

2.5 Data analysis

Ten raw files of DDA data collected from the mass spectrometer were searched by Proteome Discoverer (version: 2.1, Thermo Scientific, USA) against the Swiss-Prot Homo Sapiens Human database, which also includes the iRT sequence. The retrieval arguments contained: tryptic digestion; two missed trypsin cleavage sites were allowed; the carbamidomethyl of cysteine was set as a fixed modification; the oxidation of methionine was set as a variable modification; the fragment ion mass tolerance was 0.02 Da; and the parent ion mass tolerance was set to 10 ppm. The false discovery rate (FDR) of proteins and peptides was less than 1%. A total of 2957 protein groups were identified from the library and the result file was used in Spectronaut™ Pulsar X (Biognosys, Switzerland) software for the subsequent analysis. Nine QC and 21 raw files of DIA data were analysed with the default settings by using the Spectronaut, and the results were filtered depending on having Q-value of less than 0.01 (corresponding to an FDR of 1%). Proteins recognized by more than two unique peptides were retained. The peptide intensity was calculated by summing the peak areas of the respective fragment ions from MS2 and the protein intensity was calculated by summing the intensities of each peptide.

2.6 Statistical analysis

The missing values of protein abundance were filled with the k-nearest neighbour (K-NN) method. Differential proteins were identified by the comparison of fever samples and healthy samples with two-sided paired t-tests. The differential protein selection parameters were as follows: fold change ≥ 2 or ≤ 0.5 , p values < 0.05 (p values corrected by the BH method). Differential protein canonical pathways were generated by Ingenuity Pathway Analysis (IPA) software (Mountain View, CA, USA), and the functions of differential proteins were searched in the reported literature based on the PubMed database (<https://pubmed.ncbi.nlm.nih.gov>).

3. Results and discussion

3.1 One-to-many urine proteome analysis of single patients

3.1.1 Urine proteome analysis of F1 patient

A total of 108 differential proteins were identified by comparing the F1 sample with the healthy group samples, including 85 upregulated proteins and 23 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 2. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in LXR/RXR activation, acute phase response signaling, antigen presentation pathway, FXR/RXR activation, phagosome maturation, folate polyglutamylation, super pathway of serine and glycine biosynthesis I, sucrose degradation V, protein ubiquitination pathway and other signaling pathways. According to the relevant literature reports, the acute phase response signaling pathway^[8] is related to fever; LXR/RXR (liver X receptor/retinoid X receptor) and FXR/RXR (farnesoid-X-receptor/retinoid-X-receptor) usually exist in the biological and pathological pathways involved in glucose and lipid homeostasis and inflammatory response^[9]; antigen presentation and phagosome maturation are closely related to the immune process. At the same time, patient F1 was in an acute reaction state of fever (body temperature 38.8°C) when the samples were collected. These results indicated that the changes reflected in urine protein are consistent with clinical manifestations.

3.1.2 Urine proteome analysis of F2 patient

A total of 174 differential proteins were identified by comparing the F2 sample with the healthy group samples, including 131 upregulated proteins and 43 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 3. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in phagosome maturation, antigen presentation pathway, LXR/RXR activation, PD-L1 cancer immunotherapy pathway, Th1 and Th2 activation pathway, FXR/RXR activation, acute phase response signaling, virus entry via endocytic pathways, natural killer cell signaling, B cell development and other pathways through endocytosis. In addition to the previously mentioned signaling pathways related to inflammation, patient F2 showed more signals related to viruses and immunity, such as the signaling pathways of NK cells and B cells and the process of endocytosis of viruses into cells, which indicates that the fever is possibly caused by virus invasion. Then we searched the virus sequence, and failed to find a clear and convincing pathogenic virus. Disease-causing viruses need more in-depth examination.

3.1.3 Urine proteome analysis of F3 patient

A total of 65 differential proteins were identified by comparing the F3 sample with the healthy group samples, including 50 upregulated proteins and 15 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 4. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in acute phase response, LXR/RXR activation, FXR/RXR activation, complement system, phagosome maturation, airway pathology in chronic obstructive, bladder cancer signaling, inhibition of matrix metalloproteases, atherosclerosis signaling,

uracil degradation, thymine degradation, thyroid hormone biosynthesis, ovarian cancer signaling, tumor microenvironment pathway and other signaling pathways. Similarly, the first few pathways that are most significantly related are shown to be related to inflammation.

3.1.4 Urine proteome analysis of F4 patient

A total of 440 differential proteins were identified by comparing the F4 sample with the healthy group samples, including 279 upregulated proteins and 161 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 5. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in clathrin-mediated endocytosis signaling, epithelial adhesion junction signaling, remodeling adhesion junction signaling, BAG2 signaling pathway, synaptogenesis signaling pathway, reelin signaling in neurons and glycolysis pathway. It also has the same acute inflammation-related pathways as the F1, F2, and F3 samples.

3.1.5 Urine proteome analysis of F5 patient

A total of 184 differential proteins were identified by comparing the F5 sample with the healthy group samples, including 143 upregulated proteins and 41 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 6. $P < 0.05$ was considered to be convincing. The signaling pathways enriched by differential proteins were mainly manifested in phagosome maturation, chondroitin sulfate degradation, Ephrin receptor signaling, iron homeostasis signaling pathway, role of MAPK signaling in promoting the pathogenesis of influenza, sphingosine-1-phosphate signaling, axonal guidance signaling, RhoA signal, and so on.

3.1.6 Urine proteome analysis of F6 patient

A total of 456 differential proteins were identified by comparing the F6 sample with the healthy group samples, including 298 upregulated proteins and 158 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 7. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in LXR/RXR activation, FXR/RXR activation, phagosome maturation, acute phase response signaling, coagulation system, antigen presentation pathway, intrinsic prothrombin activation pathway, hepatic fibrosis/hepatic stellate cell activation, crosstalk between dendritic cells and natural killer cells, neuroprotective role of THOP1 in Alzheimer's disease, extrinsic prothrombin activation pathway, Th2 pathway, Th1 and Th2 activation pathway, mechanism of viral exit from host cells, atherosclerosis signaling, dendritic cell maturation, B cell development, and so on.

3.1.7 Urine proteome analysis of F7 patient

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

A total of 170 differential proteins were identified by comparing the F7 sample with the healthy group samples, including 153 upregulated proteins and 17 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 8. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in phagosome maturation, LXR/RXR activation, FXR/RXR activation, lactose degradation, phagosome formation, atherosclerosis signaling, clathrin-mediated endocytic signaling, IL-12 signaling and production in macrophages, sphingosine 1-phosphate signal, vitamin C transport pathway, remodeling of epithelial adhesion junctions, production of nitric oxide and reactive oxygen species in macrophages, caveolar-mediated endocytosis signaling, L-carnitine biosynthesis, and so on.

3.1.8 Urine proteome analysis of F8 patient

A total of 563 differential proteins were identified by comparing the F8 sample with the healthy group samples, including 460 upregulated proteins and 103 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 9. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in hepatic fibrosis/hepatic stellate cell activation, LXR/RXR activation, phagosome maturation, intrinsic prothrombin activation pathway, atherosclerosis signaling, acute phase response signaling, iron homeostasis Signal pathway, natural killer cell signaling, apelin liver signaling pathway, antigen presentation pathway, FXR/RXR activation, Th1 and Th2 activation pathway, Caveolar-mediated endocytosis signaling, Th2 pathway, complement system, and so on.

3.1.9 Urine proteome analysis of F9 patient

A total of 36 differential proteins were identified by comparing the F9 sample with the healthy group samples, including 32 upregulated proteins and 4 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 10. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in primary immunodeficiency signaling, ovarian cancer signaling, B cell development, autoimmune thyroid disease signaling, autoimmune thyroid disease signaling, neuroprotective role of THOP1 in Alzheimer's disease, dendritic cell maturation, role of NFAT in regulating of the immune response, systemic lupus erythematosus signaling, relaxin signaling, glutaryl-CoA degradation, acute phase response signaling, GNRH Signaling, B cell receptor signaling, role of JAK1, JAK2 and TYK2 in interferon signaling, NRF2-mediated oxidative stress response, and so on.

3.1.10 Urine proteome analysis of F10 patient

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

A total of 409 differential proteins were identified by comparing the F10 sample with the healthy group samples, including 272 upregulated proteins and 137 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 11. $P < 0.05$ was considered to be convincing. The signaling pathways enriched by differential proteins were mainly manifested in LXR/RXR activation, FXR/RXR activation, acute phase response signaling, phagosome maturation, antigen presentation pathway, extrinsic prothrombin activation pathway, mechanism of viral exit from host cells, ascorbate recycling, Wnt/ β -catenin signaling, atherosclerosis signaling, caveolar-mediated endocytosis signaling, natural killer cell signaling, and so on.

3.1.11 Urine proteome analysis of F11 patient

A total of 294 differential proteins were identified by comparing the F11 sample with the healthy group samples, including 217 upregulated proteins and 77 downregulated proteins. The differential protein screening parameters were $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 12. $P < 0.05$ was considered to be convincing. The signal pathways enriched by differential proteins were mainly manifested in the acute phase response signaling, antigen presentation pathway, neuroprotective role of THOP1 in Alzheimer's disease, FAT10 signaling pathway, PD-1, PD-L1 cancer immunotherapy pathway, polyamine regulation in colon cancer, BAG2 signaling pathway, protein ubiquitination pathway, phagosome maturation, LXR/RXR activation, B cell development, inhibition of ARE-mediated mRNA degradation pathway, Th2 pathway, neuroinflammation signaling pathway, role of IL-17A in psoriasis, complement system, and so on.

3.2 Group analysis of urinary proteome in patients

Nineteen samples (eleven FUO samples and eight healthy samples) were used for label-free LC-MS/MS quantitation. A total of 2812 proteins with at least 2 unique peptides were identified with $FDR < 1\%$. In addition, 129 differential proteins were identified by comparing all FUO samples with all healthy group samples, including 20 upregulated proteins and 109 downregulated proteins. $FC \geq 2$ or ≤ 0.5 , and $P < 0.05$, and the specific information on the differential proteins is listed in Table S1.

Ingenuity Pathway Analysis was used to analyse the differential proteins, and the classical pathway results obtained are listed in Table 13. $P < 0.05$ was considered to be convincing. The main signal pathways enriched by differential proteins were the STAT3 pathway, SPINK1 pancreatic cancer pathway, interleukin-15 production, and phagosome maturation, and so on. Among them, the STST3 pathway is closely related to autophagy^[10], and interleukin 15 and phagosome maturation are closely related to the body's immune system.

We performed orthogonal partial least squares (OPLS-DA) analysis on the total protein. The OPLS-DA score is shown in Figure 1. The difference between the healthy group and the patient group was relatively large, which indicates that urine protein can reflect the disease state. At the same time, the intragroup differences of the patient group were more obvious, which means that the individual differences of the clinical samples were very large. In addition, the comparison of the IPA analysis results

obtained by the single-person analysis and the group analysis shows that the group analysis will cover up the independence of individuals, which provides a theoretical basis for the significance of our single-person analysis.

3.3 Comparison of one-to-many analysis and group analysis

By comparing the results of the one-to-many analysis and the group analysis, we can observe that the results of the group analysis cannot represent the characteristics of any FUO patient. The group analysis only shows the same characteristics of the samples. In fact, each FUO patient was considered to exist independently. It is unreasonable to group them for analysis based on fever symptoms alone, and the results of 11 FUO samples were obviously different. It is worthwhile to mention that whether it is one-to-many analysis or group analysis, significant differences between FUO samples and healthy samples were found in urine, which provides a theoretical basis for clinical diagnosis of urine and, at the same time, reminds us that if there is a specific group of normal people who meet the control requirements for a specific patient as a control, it is more appropriate than using the same control for everyone, such as matching age, gender, medication history, and so on. More accurate results could be obtained if we could compare and analyse groups that match the indicators.

3.4 Parasite and virus search results

Parasite and virus databases downloaded from the UniProt website (<https://www.uniprot.org/>) were used to search for possible pathogenic factors. However, the microbes and viruses identified lacked sufficient credibility according to the current level of identification. Details are presented in Table S3.

4. Conclusions

In this study, we aimed to provide diagnostic evidence and clues for patients with fever of unknown origin (FUO) by using the one-to-many comparison label-free LC-MS/MS method. The differential proteins were screened for the analysis of biological pathways. Our results indicated that (1) the urine proteome can significantly distinguish between patients and healthy samples and (2) one-to-many comparisons can provide personalized clues for FUO patients. In fact, the individual differences in the clinical samples can easily be concealed by group analysis. One-to-many analysis can highlight the individualization of patients and it is also a way to explore clues to unknown disease patients in the future.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

CRediT authorship contribution statement

Chenyang Zhao: Conceptualization, Investigation, Writing-original draft, data curation, Visualization. **Lilong Wei:** Conceptualization, Resources, Funding acquisition. **Jing Wei:** Methodology, Investigation, formal analysis. **Youhe Gao:** Conceptualization, Writing-review & editing, Supervision, Funding acquisition.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgements

This work was supported by the National Key Research and Development Program of China (2018YFC0910202 and 2016YFC1306300); the Fundamental Research Funds for the Central Universities (2020KJZX002); the Beijing Natural Science Foundation (7172076); the Beijing Cooperative Construction Project (110651103); the Beijing Normal University (11100704). Key Clinical Specialty Project of Beijing (2020)

References

- [1] Petersdorf, R.G. and P.B. Beeson, Fever of unexplained origin: report on 100 cases. *Medicine*, 1961. 40.
- [2] Mulders–Manders, C., A. Simon, and C. Bleeker–Rovers, Fever of unknown origin. *Clinical Medicine*, 2015. 15(3): p. 280.
- [3] Gao, Y., Urine—an untapped goldmine for biomarker discovery? *Science China. Life sciences*, 2013. 56(12): p. 1145–1146.
- [4] Wu, J., Z. Guo, and Y. Gao, Dynamic changes of urine proteome in a Walker 256 tumor–bearing rat model. *Cancer medicine*, 2017. 6(11): p. 2713–2722.
- [5] Wei, J., et al., Early urine proteome changes in the Walker–256 tail–vein injection rat model. *Scientific reports*, 2019. 9(1): p. 13804.
- [6] Zhang, L., Y. Li, and Y. Gao, Early changes in the urine proteome in a diethyldithiocarbamate–induced chronic pancreatitis rat model. *Journal of proteomics*, 2018. 186.
- [7] Wisniewski, J.R., et al., Universal sample preparation method for proteome analysis. *Nat Methods*, 2009. 6(5): p. 359–62.
- [8] Koj, A., Initiation of acute phase response and synthesis of cytokines. *Biochimica et biophysica acta*, 1996. 1317(2): p. 84–94.
- [9] van Diepen, J.A., et al., Interactions between inflammation and lipid metabolism: relevance for efficacy of anti–inflammatory drugs in the treatment of atherosclerosis. *Atherosclerosis*, 2013. 228(2): p. 306–315.
- [10] ou, L., et al., The role of STAT3 in autophagy. *Autophagy*, 2015. 11(5): p. 729–739.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Figures

Figure 1. OPLS-DA analysis of identified urinary proteins.

Tables

Table 1. Clinical characteristics record of samples

Number	sex	temperature/°C
F1	female	38.8
F2	female	38.4
F3	male	37.3
F4	male	37.8
F5	male	36.0
F6	male	36.6
F7	male	36.5
F8	male	36.8
F9	female	36.6
F10	male	36.8
F11	female	36.9

Ps: The temperature recorded when collecting urine samples.

Table 2. F1 IPA analysis results

F1	Inguity Canonical Pathways	P value	Molecules
	LXR/RXR Activation	1.95E-07	AGT, APOC3, C9, CD14, HPX, LBP, ORM1, ORM2
	Acute Phase Response Signaling	3.72E-07	AGT, C9, CRP, FTL, HPX, LBP, ORM1, ORM2, SERPINA3
	Antigen Presentation Pathway	3.89E-05	B2M, CANX, HLA-DRA, HLA-DRB1
	FXR/RXR Activation	3.98E-05	AGT, APOC3, C9, HPX, ORM1, ORM2
	Phagosome Maturation	1.05E-04	B2M, CANX, CTSS, CTSZ, HLA-DRA, HLA-DRB1
	Folate Polyglutamylolation	2.45E-04	MTHFD1, SHMT1
	Superpathway of Serine and Glycine Biosynthesis I	5.13E-04	PSAT1, SHMT1
	Sucrose Degradation V (Mammalian)	6.76E-04	KHK, TKFC
	Folate Transformations I	8.71E-04	MTHFD1, SHMT1
	Hepatic Fibrosis / Hepatic Stellate Cell Activation	2.69E-03	AGT, CD14, COL5A3, LBP, MMP2
	Clathrin-mediated Endocytosis Signaling	2.82E-03	APOC3, ARPC4, DNM2, ORM1, ORM2
	Atherosclerosis Signaling	3.72E-03	APOC3, COL5A3, ORM1, ORM2
	Tryptophan Degradation X (Mammalian, via Tryptamine)	3.98E-03	AKR1A1, DDC
	TCA Cycle II (Eukaryotic)	6.31E-03	ACO1, MDH1
	Apelin Liver Signaling Pathway	7.41E-03	AGT, COL5A3
	Ovarian Cancer Signaling	7.94E-03	FSHB, MMP2, MMP7, SMO
	Aldosterone Signaling in Epithelial Cells	8.71E-03	AHCY, CRYAB, HSPB11, SMO
	Dendritic Cell Maturation	9.12E-03	B2M, CD58, COL5A3, HLA-DRA, HLA-DRB1, IGHG3
	Glycine Biosynthesis I	1.00E-02	SHMT1
	Protein Ubiquitination Pathway	1.15E-02	B2M, CRYAB, HSPB11, PSMC5, SMO

Table 3. F2 IPA analysis results

F2	Ingenuity Canonical Pathways	P value	Molecules
	Phagosome Maturation	2.14E-10	B2M, CANX, CTSB, CTSC, CTSD, CTSH, CTSS, CTSZ, HLA-A, HLA-B, HLA-C, HLA-DRA, VPS28
	Antigen Presentation Pathway	1.82E-08	B2M, CANX, CD74, HLA-A, HLA-B, HLA-C, HLA-DRA
	LXR/RXR Activation	6.31E-07	AGT, APOC2, APOC3, CD14, FGA, LCAT, ORM1, ORM2, TNFRSF1B
	PD-1, PD-L1 cancer immunotherapy pathway	1.74E-06	B2M, HLA-A, HLA-B, HLA-C, HLA-DRA, IL2RA, PDCD1, TNFRSF1B
	Th1 and Th2 Activation Pathway	7.94E-06	HLA-A, HLA-B, HLA-DRA, ICOSLG/LOC102723996, IL2RA, LGALS9, NCSTN, TGFB3, TIMD4
	Th2 Pathway	1.15E-05	HLA-A, HLA-B, HLA-DRA, ICOSLG/LOC102723996, IL2RA, NCSTN, TGFB3, TIMD4
	FXR/RXR Activation	6.46E-05	AGT, APOC2, APOC3, FGA, LCAT, ORM1, ORM2
	Acute Phase Response Signaling	1.17E-04	AGT, CP, FGA, FTL, ORM1, ORM2, SERPINA3, TNFRSF1B
	Virus Entry via Endocytic Pathways	1.86E-04	B2M, CXADR, FLNA, HLA-A, HLA-B, HLA-C
	Neuroprotective Role of THOP1 in Alzheimer's Disease	2.63E-04	AGT, CFD, HLA-A, HLA-B, HLA-C, SERPINA3
	Caveolar-mediated Endocytosis Signaling	3.31E-04	B2M, FLNA, HLA-A, HLA-B, HLA-C
	Th1 Pathway	3.55E-04	HLA-A, HLA-B, HLA-DRA, ICOSLG/LOC102723996, LGALS9, NCSTN
	Crosstalk between Dendritic Cells and Natural Killer Cells	8.13E-04	HLA-A, HLA-B, HLA-C, HLA-DRA, TNFRSF1B
	Natural Killer Cell Signaling	9.33E-04	B2M, FCGR2A, HLA-A, HLA-B, HLA-C, LAIR1, PVR
	Protein Ubiquitination Pathway	1.48E-03	B2M, CRYAB, HLA-A, HLA-B, HLA-C, HSP90AA1, HSPB11, SMO
	Coagulation System	2.69E-03	F9, FGA, PLAUR
	B Cell Development	2.95E-03	HLA-A, HLA-B, HLA-DRA
	Neuroinflammation Signaling Pathway	3.16E-03	B2M, CD200, HLA-A, HLA-B, HLA-C, HLA-DRA, NCSTN, TGFB3
	Atherosclerosis Signaling	3.39E-03	APOC2, APOC3, LCAT, ORM1, ORM2
	Mechanisms of Viral Exit from Host Cells	4.27E-03	VPS28, VPS36, VPS4A

Table 4. F3 IPA analysis results

F3	Inguity Canonical Pathways	P value	Molecules
	Acute Phase Response Signaling	7.76E-08	C3, C9, CRP, FGG, HPX, LBP, ORM1, ORM2
	LXR/RXR Activation	1.86E-06	C3, C9, HPX, LBP, ORM1, ORM2
	FXR/RXR Activation	3.72E-05	C3, C9, HPX, ORM1, ORM2
	Complement System	1.74E-04	C3, C9, CFH
	Phagosome Maturation	1.05E-03	CTSC, CTSD, CTSH, CTSZ
	Airway Pathology in Chronic Obstructive Pulmonary Disease	4.79E-03	MMP2, ORM1, ORM2
	Bladder Cancer Signaling	4.90E-03	MMP2, MMP7, THBS1
	Inhibition of Matrix Metalloproteases	5.89E-03	MMP2, MMP7
	Atherosclerosis Signaling	6.46E-03	ORM1, ORM2, PLA2G2A
	Uracil Degradation II (Reductive)	8.91E-03	DPYS
	Thymine Degradation	8.91E-03	DPYS
	Thyroid Hormone Biosynthesis	8.91E-03	CTSD
	Ovarian Cancer Signaling	1.15E-02	FSHB, MMP2, MMP7
	Granulocyte Adhesion and Diapedesis	1.55E-02	MMP2, MMP7, PF4
	Tumor Microenvironment Pathway	1.66E-02	IGF2, MMP2, MMP7
	Agrin Interactions at Neuromuscular Junction	1.78E-02	DAG1, LAMC1
	Hepatic Fibrosis / Hepatic Stellate Cell Activation	1.95E-02	IGF2, LBP, MMP2
	Adrenomedullin signaling pathway	2.09E-02	C3, CFH, MMP2
	Ceramide Degradation	2.09E-02	ASAHI
	Agranulocyte Adhesion and Diapedesis	2.14E-02	MMP2, MMP7, PF4

Table 5. F4 IPA analysis results

F4	Inguity Canonical Pathways	P value	Molecules
	Clathrin-mediated Endocytosis Signaling	3.16E-16	ACTA1, ACTG1, ACTR2, ACTR3, APOA1, APOA2, APOA4, APOB, APOC1, APOC2, APOC3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, CDC42, CLTC, DNM2, F2, HSPA8, MYO6, ORM1, ORM2, SAA4, WASL
	Epithelial Adherens Junction Signaling	6.31E-11	ACTA1, ACTG1, ACTN4, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, BAIAP2, CDC42, CDH2, NECTIN1, NECTIN3, NOTCH2, PTPRM, WASL
	Remodeling of Epithelial Adherens Junctions	6.46E-10	ACTA1, ACTG1, ACTN4, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, DNM2
	BAG2 Signaling Pathway	8.71E-10	CTSB, HSP90AA1, HSPA4, HSPA8, MAPT, PSMA4, PSMA6, PSMA7, PSMC2, PSMC3, PSMC5, PSMC6, PSMD2, PSME1
	Synaptogenesis Signaling Pathway	4.57E-09	ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, CADM1, CDC42, CDH16, CDH2, CFL1, EFNA1, EFNA2, EFNA4, EPHA1, EPHB4, HSPA8, MAPT, NECTIN1, NECTIN3, STXB2, WASL
	Reelin Signaling in Neurons	5.25E-09	ACTR2, ACTR3, APP, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, CDC42, CDH2, CFL1, MAPT, NECTIN3, WASL
	Glycolysis I	1.51E-08	ALDOB, ENO1, FBPI, GAPDH, GPI, PFKL, PFKM, PGK1
	RhoA Signaling	2.75E-08	ACTA1, ACTG1, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, BAIAP2, CFL1, CFL2, EPHA1
	Acute Phase Response Signaling	4.27E-08	A2M, APOA1, APOA2, C1QC, C3, CRP, F2, FGB, FGG, FTL, IL1RAP, IL6ST, ITIH2, ORM1, ORM2, RBP5, SAA4, VWF
	Regulation of Actin-based Motility by Rho	5.13E-08	ACTA1, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, BAIAP2, CDC42, CFL1, WASL
	Ephrin Receptor Signaling	1.45E-07	ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, CDC42, CFL1, CFL2, EFNA1, EFNA2, EFNA4, EPHA1, EPHB4, WASL
	LXR/RXR Activation	2.14E-07	APOA1, APOA2, APOA4, APOB, APOC1, APOC2, APOC3, C3, IL1RAP, KNG1, LCAT, ORM1, ORM2, SAA4
	FXR/RXR Activation	2.63E-07	APOA1, APOA2, APOA4, APOB, APOC1, APOC2, APOC3, C3, FBPI, KNG1, LCAT, ORM1, ORM2, SAA4
	Atherosclerosis Signaling	2.88E-07	APOA1, APOA2, APOA4, APOB, APOC1, APOC2, APOC3, COL1A2, COL5A3, CSF1, LCAT, ORM1, ORM2, SAA4
	Actin Nucleation by ARP-WASP Complex	3.16E-07	ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, BAIAP2, CDC42, WASL
	Rho GDI Signaling	3.72E-07	ACTA1, ACTG1, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, CD44, CDC42, CDH16, CDH2, CFL1, CFL2, WASL
	Coagulation System	3.98E-07	A2M, F2, F5, FGB, FGG, KNG1, TFPI, VWF
	Phagosome Maturation	3.98E-07	ATP6AP2, ATP6V0A1, ATP6V1G1, ATP6V1H, CANX, CTSA, CTSB, CTSC, CTSH, CTSS, CTSZ, DYNC1H1, HLA-DRA, HLA-DRB1, VPS37B
	Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes	3.98E-07	ACTA1, ACTG1, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, CDC42
	Gluconeogenesis I	4.79E-07	ALDOB, ENO1, FBPI, GAPDH, GPI, MDH1, PGK1

Table 6. F5 IPA analysis results

F5	Inguinity Canonical Pathways	P value	Molecules
	Phagosome Maturation	1.58E-14	ATP6V0A4, ATP6V1A, ATP6V1B1, ATP6V1E1, ATP6V1G1, ATP6V1H, CTSA, CTSC, CTSD, CTSH, CTSS, CTSZ, HLA-DRA, HLA-DRB1, LAMP1, PRDX5
	Chondroitin Sulfate Degradation (Metazoa)	8.71E-08	ARSB, GALNS, GM2A, HEXA, HEXB
	Ephrin Receptor Signaling	1.38E-06	CDC42, EFNA2, EFNA4, EPHA1, EPHB2, GNA11, GNA13, GNAI3, GNAQ, PTPN13, RAPIA
	Iron homeostasis signaling pathway	2.51E-06	ATP6V0A4, ATP6V1A, ATP6V1B1, ATP6V1E1, ATP6V1G1, ATP6V1H, HSPA9, PDGFRB, SMAD3
	Role of MAPK Signaling in Promoting the Pathogenesis of Influenza	5.01E-06	ATP6V0A4, ATP6V1A, ATP6V1B1, ATP6V1E1, ATP6V1G1, ATP6V1H, LCAT, RAPIA
	Sphingosine-1-phosphate Signaling	7.41E-06	ASAH1, CDC42, GNA13, GNAI3, GNAQ, PDGFRB, RHOF, SMPD1
	Sperm Motility	9.77E-06	AXL, EPHA1, EPHB2, FRK, GNA11, GNA13, GNAI3, GNAQ, LCAT, PDGFRB, TYRO3
	Ephrin B Signaling	3.80E-05	CDC42, EPHB2, GNA11, GNA13, GNAI3, GNAQ
	RhoA Signaling	9.55E-05	BAIAP2, EPHA1, EZR, GNA13, MSN, PFN2, RDX
	Axonal Guidance Signaling	9.77E-05	ADAM9, BAIAP2, CDC42, CHP1, EFNA2, EFNA4, EPHA1, EPHB2, GNA11, GNA13, GNAI3, GNAQ, PFN2, RAPIA
	Gaq Signaling	1.00E-04	CDC42, CHP1, GNA11, GNA13, GNAI3, GNAQ, PLD3, RHOF
	RhoGDI Signaling	1.02E-04	CDC42, EZR, GNA11, GNA13, GNAI3, GNAQ, MSN, RDX, RHOF
	Signaling by Rho Family GTPases	1.12E-04	BAIAP2, CDC42, EZR, GNA11, GNA13, GNAI3, GNAQ, MSN, RDX, RHOF
	Systemic Lupus Erythematosus In T Cell Signaling Pathway	1.26E-04	CDC42, CHP1, EZR, GNA13, GNAI3, HLA-DRA, HLA-DRB1, ICOSLG/LOC102723996, MSN, RAPIA, RDX, RHOF
	G Beta Gamma Signaling	1.35E-04	CDC42, DNM2, GNA11, GNA13, GNAI3, GNAQ, RAPIA
	fMLP Signaling in Neutrophils	1.45E-04	CDC42, CHP1, GNA11, GNA13, GNAI3, GNAQ, RAPIA
	Apelin Endothelial Signaling Pathway	2.04E-04	AQP2, GNA11, GNA13, GNAI3, GNAQ, RAPIA, SMAD3
	Dermatan Sulfate Degradation (Metazoa)	2.69E-04	GM2A, HEXA, HEXB
	Relaxin Signaling	3.47E-04	ENPP6, GDDPD3, GNA11, GNA13, GNAI3, GNAQ, RAPIA
	IL-8 Signaling	4.68E-04	CDC42, GNA11, GNA13, GNAI3, GNAQ, PLD3, RAPIA, RHOF

Table 7. F6 IPA analysis results

F6	Ingenuity Canonical Pathways		Molecules	
		P value		
	LXR/RXR Activation	7.94E-15	A1BG, AGT, AMBP, APOC2, APOC3, C4A/C4B, CD14, CETP, FGA, GC, HPX, IL1R2, ITIH4, KNG1, LBP, LCAT, ORM1, ORM2, RBP4, SERPINA1, TF, TNFRSF1A	
	FXR/RXR Activation	1.26E-12	A1BG, ABCC2, AGT, AMBP, APOC2, APOC3, C4A/C4B, CETP, FETUB, FGA, GC, HPX, ITIH4, KNG1, LCAT, ORM1, ORM2, RBP4, SERPINA1, TF	
	Phagosome Maturation	3.98E-12	ATP6V1B1, B2M, CALR, CANX, CTSA, CTSB, CTSC, CTSD, CTSH, CTSL, CTSS, CTSZ, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, LAMP1, TSG101, VPS28, VPS37B	
	Acute Phase Response Signaling	5.01E-12	AGT, AMBP, C2, C4A/C4B, CFB, CP, CRP, FGA, FTL, HPX, IL6ST, ITIH4, LBP, ORM1, ORM2, PLG, RBP4, RBP5, SERPINA1, SERPINA3, SOD2, TF, TNFRSF1A	
	Coagulation System	1.41E-09	F10, F5, F9, FGA, KNG1, PLAUR, PLG, PROS1, SERPINA1, SERPINC1	
	Antigen Presentation Pathway	3.47E-09	B2M, CALR, CANX, CD74, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, PDIA3	
	Intrinsic Prothrombin Activation Pathway	1.58E-06	COL1A1, F10, F5, F9, FGA, KNG1, PROS1, SERPINC1	
	Hepatic Fibrosis / Hepatic Stellate Cell Activation	2.14E-06	AGT, CCN2, CD14, COL1A1, COL6A3, ICAM1, IFNAR2, IGF2, IGF1BP3, IL1R2, LBP, PDGFRA, PDGFRB, TIMP2, TNFRSF1A, VCAM1	
	Crosstalk between Dendritic Cells and Natural Killer Cells	2.63E-06	CD83, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, ICAM3, IL2RB, LTBR, NECTIN2, TLN1	
	Neuroprotective Role of THOP1 in Alzheimer's Disease	3.09E-06	AGT, CFD, DPP4, HLA-A, HLA-B, HLA-C, HPN, HTRA3, KNG1, PLG, PRSS8, SERPINA3	
	Extrinsic Prothrombin Activation Pathway	1.29E-05	F10, F5, FGA, PROS1, SERPINC1	
	Th2 Pathway	2.00E-05	DLL1, HLA-A, HLA-B, HLA-DRA, HLA-DRB1, ICAM1, ICOSLG/LOC102723996, IL2RB, NCSTN, NOTCH2, TGFB3, TIMD4	
	Th1 and Th2 Activation Pathway	4.37E-05	DLL1, HLA-A, HLA-B, HLA-DRA, HLA-DRB1, ICAM1, ICOSLG/LOC102723996, IL10RB, IL2RB, NCSTN, NOTCH2, TGFB3, TIMD4	
	PD-1, PD-L1 cancer immunotherapy pathway	5.25E-05	B2M, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, IL2RB, PDCD1, PDCD1LG2, TNFRSF1A	
	Iron homeostasis signaling pathway	9.77E-05	ATP6V1B1, CP, FTH1, FTL, GDF15, HJV, HPX, PDGFRA, PDGFRB, SLC39A14, TF	
	Th1 Pathway	1.51E-04	DLL1, HLA-A, HLA-B, HLA-DRA, HLA-DRB1, ICAM1, ICOSLG/LOC102723996, IL10RB, NCSTN, NOTCH2	
	Mechanisms of Viral Exit from Host Cells	1.78E-04	CHMP2B, CHMP4C, PDCD6IP, TSG101, VPS28, VPS4A	
	Atherosclerosis Signaling	2.82E-04	APOC2, APOC3, COL1A1, ICAM1, LCAT, ORM1, ORM2, RBP4, SERPINA1, VCAM1	
	Dendritic Cell Maturation	4.68E-04	B2M, CD58, CD83, COL1A1, FCGR2A, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, ICAM1, IGHG2, IGHG3, IGLC3, LTBR, LY75, PDIA3, TNFRSF1A	
	B Cell Development	7.94E-04	HLA-A, HLA-B, HLA-DRA, HLA-DRB1, IGHM	

Table 8. F7 IPA analysis results

F7	Inguity Canonical Pathways	P value	Molecules
	Phagosome Maturation	2.82E-06	ATP6V0A1, CTSA, CTSH, CTSS, HLA-C, HLA-DRA, LAMP1, RAB7A, TUBB4B
	LXR/RXR Activation	5.50E-05	APOC1, APOC2, C9, IL18, LBP, LCAT, PCYOX1
	FXR/RXR Activation	4.68E-04	APOC1, APOC2, C9, IL18, LCAT, PCYOX1
	Lactose Degradation III	6.03E-04	GLB1, PSAP
	Phagosome Formation	7.94E-04	C3AR1, CDC42, CLEC7A, FCAMR, MRC2, RHOF
	Atherosclerosis Signaling	3.24E-03	APOC1, APOC2, IL18, LCAT, PCYOX1
	Clathrin-mediated Endocytosis Signaling	4.17E-03	APOC1, APOC2, CDC42, DNM2, PCYOX1, RAB7A
	IL-12 Signaling and Production in Macrophages	4.17E-03	APOC1, APOC2, IL18, PCYOX1, RAB7A
	PD-1, PD-L1 cancer immunotherapy pathway	8.91E-03	HLA-C, HLA-DRA, IL2RA, PDCD1
	Th1 and Th2 Activation Pathway	1.05E-02	HLA-DRA, IL18, IL2RA, LGALS9, NCSTN
	Sphingosine-1-phosphate Signaling	1.29E-02	ASAHI, CDC42, PDGFRB, RHOF
	Th1 Pathway	1.38E-02	HLA-DRA, IL18, LGALS9, NCSTN
	Vitamin-C Transport	1.41E-02	SLC23A1, STOM
	Acute Phase Response Signaling	1.51E-02	C9, CRP, FTL, IL18, LBP
	Remodeling of Epithelial Adherens Junctions	1.51E-02	DNM2, RAB7A, TUBB4B
	Agrin Interactions at Neuromuscular Junction	1.66E-02	CDC42, LAMB1, LAMC1
	Production of Nitric Oxide and Reactive Oxygen Species in Macrophages	1.66E-02	APOC1, APOC2, CDC42, PCYOX1, RHOF
	Caveolar-mediated Endocytosis Signaling	2.14E-02	DNM2, FLOT1, HLA-C
	L-carnitine Biosynthesis	2.34E-02	BBOX1
	LPS/IL-1 Mediated Inhibition of RXR Function	3.02E-02	ALDH2, APOC1, APOC2, IL18, LBP

Table 9. F8 IPA analysis results

	Ingenuity Canonical Pathways	P value	Molecules
F8	Hepatic Fibrosis / Hepatic Stellate Cell Activation	1.26E-11	BAX, CCN2, CD14, CD40, COL15A1, COL18A1, COL1A1, COL1A2, COL3A1, COL4A1, COL5A3, COL6A3, FGFR1, IFNAR2, IGF2, IGFBP3, LBP, MMP9, PDGFRA, PDGFRB, TGFB1, TIMP2, TNFRSF1A, TNFRSF1B, VCAM1
	LXR/RXR Activation	7.94E-08	APOC3, CD14, GC, HPX, KNG1, LBP, LCAT, LPL, MMP9, ORM1, ORM2, PLTP, RBP4, SERPINF2, TNFRSF1A, TNFRSF1B
	Phagosome Maturation	2.14E-07	ATP6AP1, ATP6V0A1, B2M, CANX, CTSA, CTSD, CTSH, CTSS, CTSZ, HLA-A, HLA-B, HLA-C, HLA-DRB1, LAMP1, PRDX5, VPS28
	Intrinsic Prothrombin Activation Pathway	6.31E-07	COL18A1, COL1A1, COL1A2, COL3A1, COL5A3, F10, F5, F9, KNG1
	Atherosclerosis Signaling	6.46E-07	APOC3, CD40, COL18A1, COL1A1, COL1A2, COL3A1, COL5A3, LCAT, LPL, MMP9, ORM1, ORM2, RBP4, TNFRSF1A, TNFRSF1B
	Acute Phase Response Signaling	9.55E-07	C2, CFB, CP, CRP, FTL, GRB2, HPX, LBP, ORM1, ORM2, OSMR, RBP4, SERPINA3, SERPINF2, SERPING1, SOD2, TNFRSF1A, TNFRSF1B
	Iron homeostasis signaling pathway	6.61E-06	ATP6AP1, ATP6V0A1, BMP6, CD163, CP, FTH1, FTL, GDF15, HJV, HPX, PDGFRA, PDGFRB, SKP1, SLC39A14
	Natural Killer Cell Signaling	3.09E-05	B2M, COL18A1, COL1A1, COL1A2, COL3A1, COL5A3, FCGR2A, GRB2, HLA-A, HLA-B, HLA-C, IL2RB, LAIR1, LILRB1, PVR, ULBP2
	Apelin Liver Signaling Pathway	3.63E-05	COL18A1, COL1A1, COL1A2, COL3A1, COL5A3, PDGFRB
	Antigen Presentation Pathway	3.89E-05	B2M, CANX, HLA-A, HLA-B, HLA-C, HLA-DRB1, PDIA3
	FXR/RXR Activation	7.41E-05	APOC3, GC, HPX, KNG1, LCAT, LPL, ORM1, ORM2, PCK2, PLTP, RBP4, SERPINF2
	Th1 and Th2 Activation Pathway	8.51E-05	CD40, GRB2, HLA-A, HLA-B, HLA-DRB1, ICOSLG/LOC102723996, IL10RB, IL2RA, IL2RB, LGALS9, NCSTN, NOTCH2, TGFB1, TIMD4
	Crosstalk between Dendritic Cells and Natural Killer Cells	9.55E-05	CD40, CD83, HLA-A, HLA-B, HLA-C, HLA-DRB1, IL2RB, LTBR, TLN1, TNFRSF1B
	Caveolar-mediated Endocytosis Signaling	1.07E-04	B2M, COPB2, DNM2, FLNA, FLNC, HLA-A, HLA-B, HLA-C, ITGB5
	Neuroprotective Role of THOP1 in Alzheimer's Disease	1.10E-04	APP, DPP4, HLA-A, HLA-B, HLA-C, HTRA1, HTRA3, KNG1, MMP9, PRSS23, SERPINA3
	Th2 Pathway	1.35E-04	CD40, GRB2, HLA-A, HLA-B, HLA-DRB1, ICOSLG/LOC102723996, IL2RA, IL2RB, NCSTN, NOTCH2, TGFB1, TIMD4
	Phagosome Formation	1.91E-04	C3AR1, CLEC7A, FCAMR, FCGR2A, IGHG3, IGHG4, IGLC3, ITGB5, MARCKS, MRC1, MRC2, PDIA3
	Coagulation System	2.14E-04	F10, F5, F9, KNG1, PLAUR, SERPINF2
	Complement System	2.51E-04	C2, C3AR1, C8G, CD46, CFB, SERPING1
	PD-1, PD-L1 cancer immunotherapy pathway	2.63E-04	B2M, HLA-A, HLA-B, HLA-C, HLA-DRB1, IL2RA, IL2RB, PDCD1LG2, TNFRSF1A, TNFRSF1B

Table 10. F9 IPA analysis results

F9	Ingenuity Canonical Pathways	P value	Molecules
	Primary Immunodeficiency Signaling	4.79E-05	IGHG2, IGHM, IGLL1/IGLL5
	Ovarian Cancer Signaling	7.94E-05	CGA, FSHB, LHB, MMP9
	B Cell Development	1.29E-03	HLA-DRB1, IGHM
	Autoimmune Thyroid Disease Signaling	4.37E-03	CGA, HLA-DRB1, IGHG2
	Communication between Innate and Adaptive Immune Cells	6.92E-03	HLA-DRB1, IGHG2, IGHM
	Neuroprotective Role of THOP1 in Alzheimer's Disease	1.17E-02	MMP9, SERPINA3
	Superoxide Radicals Degradation	1.17E-02	SOD1
	Dendritic Cell Maturation	1.55E-02	FCGR3A/FCGR3B, HLA-DRB1, IGHG2
	Role of NFAT in Regulation of the Immune Response	1.58E-02	FCGR3A/FCGR3B, HLA-DRB1, IGHM
	Phagosome Formation	1.78E-02	FCGR3A/FCGR3B, IGHG2
	Systemic Lupus Erythematosus Signaling	1.95E-02	FCGR3A/FCGR3B, IGHG2, IGHM
	Phagosome Maturation	2.04E-02	HLA-DRB1, PRDX2
	Relaxin Signaling	2.09E-02	GDPD3, MMP9
	Glutaryl-CoA Degradation	2.51E-02	CA1
	Acute Phase Response Signaling	3.02E-02	FTL, SERPINA3
	GNRH Signaling	3.02E-02	FSHB, LHB
	B Cell Receptor Signaling	3.16E-02	IGHG2, IGHM
	Tryptophan Degradation III (Eukaryotic)	3.47E-02	CA1
	Role of JAK1, JAK2 and TYK2 in Interferon Signaling	3.80E-02	CGA
	NRF2-mediated Oxidative Stress Response	3.89E-02	FTL, SOD1

Table 11. F10 IPA analysis results

F10	Inguity Canonical Pathways	P value	Molecules
	LXR/RXR Activation	7.94E-15	A1BG, AGT, AHSB, AMBP, APOC2, APOC3, C4A/C4B, C9, CD14, FGA, HPX, KNG1, LBP, LCAT, ORM1, ORM2, PLTP, RBP4, SERPINA1, TF, TNFRSF1A
	FXR/RXR Activation	1.58E-12	A1BG, AGT, AHSB, AMBP, APOC2, APOC3, C4A/C4B, C9, FETUB, FGA, HPX, KNG1, LCAT, ORM1, ORM2, PLTP, RBP4, SERPINA1, TF
	Acute Phase Response Signaling	2.51E-11	AGT, AHSB, AMBP, C4A/C4B, C9, CP, CRP, FGA, FTL, HP, HPX, LBP, ORM1, ORM2, PLG, RBP4, RBP5, SERPINA1, SERPINA3, TF, TNFRSF1A
	Phagosome Maturation	3.16E-11	ATP6V1B2, B2M, CALR, CANX, CTSB, CTSC, CTSH, CTSS, CTSZ, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, RAB5C, TSG101, VPS28, VPS37B
	Coagulation System	9.77E-09	F10, F11, F5, F9, FGA, KNG1, PLG, SERPINA1, SERPINC1
	Antigen Presentation Pathway	2.14E-08	B2M, CALR, CANX, CD74, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1
	Neuroprotective Role of THOP1 in Alzheimer's Disease	9.33E-07	AGT, CFD, DPP4, F11, HLA-A, HLA-B, HLA-C, HTRA1, HTRA3, KNG1, PLG, SERPINA3
	Intrinsic Prothrombin Activation Pathway	8.71E-06	F10, F11, F5, F9, FGA, KNG1, SERPINC1
	PD-1, PD-L1 cancer immunotherapy pathway	1.17E-04	B2M, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, IL2RB, PDCD1, TNFRSF1A
	Extrinsic Prothrombin Activation Pathway	1.70E-04	F10, F5, FGA, SERPINC1
	Hepatic Fibrosis / Hepatic Stellate Cell Activation	2.09E-04	AGT, CD14, COL4A1, COL6A3, IFNAR2, IGF2, IGFBP4, LBP, PDGFRB, TIMP2, TNFRSF1A, VCAM1
	Clathrin-mediated Endocytosis Signaling	2.29E-04	APOC2, APOC3, CD2AP, DAB2, EPHB2, ORM1, ORM2, RAB5C, RBP4, SERPINA1, TF, TSG101
	LPS/IL-1 Mediated Inhibition of RXR Function	7.94E-04	ALDH1L1, ALDH2, APOC2, CD14, FABP1, FABP2, FABP3, FABP7, GSTO1, LBP, PLTP, TNFRSF1A
	Mechanisms of Viral Exit from Host Cells	8.71E-04	CHMP4B, PDCD6IP, TSG101, VPS28, VPS4A
	Ascorbate Recycling (Cytosolic)	1.00E-03	GLRX, GSTO1
	Wnt/ β -catenin Signaling	1.20E-03	CD44, CDH2, CDH3, CDH5, DKK3, FRZB, GNAQ, KREMEN1, SFRP4, SMO
	Atherosclerosis Signaling	2.29E-03	APOC2, APOC3, LCAT, ORM1, ORM2, RBP4, SERPINA1, VCAM1
	Caveolar-mediated Endocytosis Signaling	2.51E-03	B2M, FLNC, HLA-A, HLA-B, HLA-C, RAB5C
	Natural Killer Cell Signaling	3.09E-03	B2M, FCGR2A, HLA-A, HLA-B, HLA-C, HSPA4, IL2RB, LAIR1, PVR, ULBP2
	Iron homeostasis signaling pathway	3.16E-03	ATP6V1B2, CP, FTL, GDF15, HP, HPX, PDGFRB, TF

Table 12. F11 IPA analysis results

F11	Inguity Canonical Pathways	P value	Molecules
	Acute Phase Response Signaling	1.45E-10	AGT, APOH, C1R, C1S, C2, CP, CRP, FTL, IL6ST, ORM1, ORM2, PLG, RBP5, SERPINA3, SERPING1, SOD2, TNFRSF1B
	Antigen Presentation Pathway	6.92E-10	B2M, CANX, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, PDIA3, PSMB9
	Neuroprotective Role of THOP1 in Alzheimer's Disease	1.32E-07	AGT, C1R, DPP4, HLA-A, HLA-B, HLA-C, HPN, KLRK6, PLG, PRTN3, SERPINA3
	FAT10 Signaling Pathway	3.09E-07	PSMA1, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB4, PSMB9
	PD-1, PD-L1 cancer immunotherapy pathway	6.03E-07	B2M, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, IL2RB, PDCD1, PDCD1LG2, TNFRSF1B
	Polyamine Regulation in Colon Cancer	7.08E-07	PSMA1, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB4, PSMB9
	BAG2 Signaling Pathway	7.24E-06	PSMA1, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB4, PSMB9
	Protein Ubiquitination Pathway	7.24E-06	B2M, CRYAB, HLA-A, HLA-B, HLA-C, HSPB11, PSMA1, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB4, PSMB9
	Phagosome Maturation	1.70E-05	B2M, CANX, CTSS, CTSZ, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, LAMP1
	LXR/RXR Activation	2.24E-05	A1BG, AGT, APOC1, APOH, CD14, ORM1, ORM2, S100A8, TNFRSF1B
	B Cell Development	7.59E-05	HLA-A, HLA-B, HLA-DRA, HLA-DRB1, IGHM
	Crosstalk between Dendritic Cells and Natural Killer Cells	1.35E-04	HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, IL2RB, TNFRSF1B
	Inhibition of ARE-Mediated mRNA Degradation Pathway	1.66E-04	PSMA1, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB4, PSMB9, TNFRSF1B
	Th2 Pathway	2.51E-04	HLA-A, HLA-B, HLA-DRA, HLA-DRB1, ICOSLG/LOC102723996, IL2RB, NCSTN, TGFB3
	Caveolar-mediated Endocytosis Signaling	3.31E-04	B2M, COPB2, HLA-A, HLA-B, HLA-C, ITGB1
	Neuroinflammation Signaling Pathway	4.37E-04	B2M, CD200, CRP, CX3CL1, HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, NCSTN, SOD2, TGFB3
	Role of IL-17A in Psoriasis	6.17E-04	S100A7, S100A8, S100A9
	Huntington's Disease Signaling	6.76E-04	CAPN1, CAPNS1, GNAQ, PSMA1, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB4, PSMB9
	FXR/RXR Activation	9.33E-04	A1BG, ABCC2, AGT, APOC1, APOH, ORM1, ORM2
	Complement System	9.77E-04	C1R, C1S, C2, SERPING1

Table 13. FUGO samples IPA analysis results

F	Ingenuity Canonical Pathways	P value	Molecules
	STAT3 Pathway	1.74E-04	EGF, FGFR1, FGFR3, GHR, IL2RB, PDGFRB
	SPINK1 Pancreatic Cancer Pathway	3.47E-04	CPM, CTSA, CTSC, KLK1
	IL-15 Production	8.32E-04	EPHB3, ERBB4, FGFR1, FGFR3, PDGFRB
	Iron homeostasis signaling pathway	1.32E-03	CP, CREB3L3, EGF, FTL, PDGFRB
	Hepatic Fibrosis / Hepatic Stellate Cell Activation	6.03E-03	COL15A1, EGF, FGFR1, PDGFRB, TIMP2
	Synaptogenesis Signaling Pathway	1.12E-02	CADM1, CDH19, CREB3L3, EPHB3, EPHB6, NECTIN3
	Phagosome Maturation	1.29E-02	CTSA, CTSC, CTSC, CTSS
	PTEN Signaling	1.32E-02	FGFR1, FGFR3, GHR, PDGFRB
	FGF Signaling	1.45E-02	CREB3L3, FGFR1, FGFR3
	Sperm Motility	1.66E-02	EPHB3, ERBB4, FGFR1, FGFR3, PDGFRB
	Coagulation System	1.91E-02	KNG1, SERPINA5
	Intrinsic Prothrombin Activation Pathway	2.57E-02	KLK1, KNG1
	Regulation Of The Epithelial Mesenchymal Transition By Growth Factors Pathway	2.95E-02	EGF, FGFR1, FGFR3, PDGFRB
	Neuroprotective Role of THOP1 in Alzheimer's Disease	3.02E-02	HGFAC, KLK1, KNG1
	Regulation of the Epithelial-Mesenchymal Transition Pathway	3.02E-02	EGF, FGFR1, FGFR3, PDGFRB
	Ephrin Receptor Signaling	3.31E-02	CREB3L3, EGF, EPHB3, EPHB6
	Ceramide Degradation	4.17E-02	ASAH1
	CNTF Signaling	4.57E-02	CNTFR, LIFR
	Adipogenesis pathway	4.68E-02	DLK1, FGFR1, FGFR3
	White Adipose Tissue Browning Pathway	4.90E-02	CREB3L3, FGFR1, FGFR3